Sudeep Pharma Limited DCF Valuation
SUDEEPPHRM · Chemicals · Current price ₹1,020
Sudeep Pharma Limited cash-flow valuation
Our discounted cash flow (2-stage) values Sudeep Pharma Limited at ₹60 per share. implied value is <0.2× the price (likely a data error). A discounted cash flow is only as good as the cash-flow path it assumes, so the assumptions behind it are listed in full below.
Try your own assumptions
Prefer to build the discounted cash flow yourself? The DCF calculator below opens pre-filled with Sudeep Pharma Limited's reported free cash flow, net debt and share count, so you can set your own growth and discount rate.
How we got this fair value
Every number below is part of the same estimate for Sudeep Pharma Limited. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹1,004 – ₹1,227
Why this method for this business
The pharmaceutical sector is earnings-driven with durable moats, making the relative P/E and DCF models appropriate. The DCF accounts for growth and discount rates, while the P/E captures market sentiment and sector multiples.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
implied value is <0.2× the price (likely a data error)
- ev_ebitda is less relevant for a high-ROE, asset-light pharma company
- book-value models are not suitable for a high-growth, earnings-driven business
What was missing
- Lack of historical P/E data for the company
- Limited analyst coverage for forward estimates
- No detailed capital allocation data
What drives it
14 inputs, grouped by how strong each claim is
- Sector-median P/E
- 38.07×
- Peers used
- 41
- EPS (TTM)
- 16.83 ₹/share
peer-median
peer-median
computed
- Term: quality
- +13.1%
- Term: growth
- +40.0%
- Term: capital_allocation
- +1.7%
- Term: financial_strength
- +6.8%
- Term: history
- +0.0%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
quality 81/100 (high, stable returns) → premium
durable ~32% CAGR (ROCE 36% > hurdle) → premium
capital allocation: steady → neutral
financial strength: low leverage (D/E 0.2) → mild premium
history: no reliable own-history P/E → not used
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- +74.1%
- Fair-multiple confidence
- 62%
- Fair P/E
- 66.27×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Sudeep Pharma Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on Sudeep Pharma Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.